Home / Intelligence / Webinars / IRA Medicare Inflation Penalties: Implications for Manufacturer Pricing and Contract Strategy Decision Making
Available On Demand
What do ‘pricing inflation penalties’ actually mean for manufacturers of biopharma products?
Explore the impact of the Inflation Reduction Act (IRA) on biopharmaceutical product net prices and contract strategies as manufacturers adapt to new U.S. market conditions.
In this webinar, Trinity Life Sciences’ Evidence, Value, Access & Pricing practice experts will provide a high-level review of IRA policy updates before exploring the implications for currently marketed Medicare Part B and Part D therapies, as well as for future product launches.
Don’t miss your chance to gain an in-depth understanding of the IRA’s ramifications on future product pricing, contracting and net revenues. Register for our webinar to explore representative case studies that demonstrate a number of price management actions that manufacturers can use to avoid the penalties, but also understand situations in which accepting penalty rebates could actually optimize brand net revenues.
Key Topics
- Overview of key policy updates in the Inflation Reduction Act
- Deep dive into the impact of the Inflation Reduction Act on pricing
- Recommendations about the actions and strategies to explore in addressing inflation penalties
Complete the form below to watch the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Looking Ahead to the November Election and Beyond
August 14, 2024 | 1:00 – 2:00 PM ET
As healthcare policy and the access landscape evolve, biopharma companies face challenges in navigating this ever-changing space. To help organizations prepare for and adapt to these changes, Trinity Life Sciences is offering a new webinar series, The Next Era in U.S. Healthcare Policy & Access. Join us for the first webinar in the series, Looking Ahead […]
Sign Up Now
Blog
Developing Effective Global Value Dossiers
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center […]
Read More
Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]
Read More